COYATAPIACOYA TAPIA11782TAPIA, COYAAssistant Professorplugins:FeaturedVideosFeatured Videosplugins:TwitterTwitterprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:orcidIdORCID idvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonBreast Medical OncologyEndocrine Neoplasia & HDInvestigational Cancer TherapeuticsLeukemiaMolecular & Cellular OncologySystems BiologyTranslational Molecular PathologyMD AndersonMIEN-CHIEHUNGMIEN-CHIE HUNG8427HUNG, MIEN-CHIEProfessorARGUNAKCAKANATARGUN AKCAKANAT9251AKCAKANAT, ARGUNAssistant ProfessorNAOTO TUENONAOTO T UENO8465UENO, NAOTO TProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorGORDON BMILLSGORDON B MILLS8620MILLS, GORDON BProfessorMOUHAMMED AHABRAMOUHAMMED A HABRA9548HABRA, MOUHAMMED AAssociate ProfessorFUNDAMERIC-BERNSTAMFUNDA MERIC-BERNSTAM8778MERIC-BERNSTAM, FUNDAProfessorAUNGNAINGAUNG NAING9382NAING, AUNGAssociate Professor74Professor10Assistant Professor14Associate Professor1515 Holcombe Blvd.Houston77030TX0.8714320.00635345202research areas1.702260.040111655coauthor of23.80135.6467660similar to1136selected publicationsAuthorship 842727Authorship 850239Authorship 851750Authorship 857642Authorship 863909Molecular and Cellular EndocrinologyGenes and proteins of the alternative steroid backdoor pathway for dihydrotestosterone synthesis are expressed in the human ovary and seem enhanced in the polycystic ovary syndrome. Molecular and Cellular Endocrinology. Genes and proteins of the alternative steroid backdoor pathway for dihydrotestosterone synthesis are expressed in the human ovary and seem enhanced in the polycystic ovary syndromeAnnals of Surgical OncologyInterobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Annals of Surgical Oncology. 1-7.Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working GroupBMC CancerAndrogen receptor status is highly conserved during tumor progression of breast cancer. BMC Cancer. 15.Androgen receptor status is highly conserved during tumor progression of breast cancerPLoS OneStandardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PLoS One. 10.Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 studyRadiation OncologyDose escalated intensity modulated radiotherapy in the treatment of cervical cancer. Radiation Oncology. 10.Dose escalated intensity modulated radiotherapy in the treatment of cervical cancerD018734Genes & Molecular Sequences1242300.905009Genes, erbB-2D018719Chemicals & Drugs51925130.48603Receptor, ErbB-2D035583Disorders2323500.770865Rare DiseasesAuthorship 8974566Authorship 9008326Authorship 9013927Authorship 9014348Authorship 9054907Authorship 9085536Authorship 9191498Authorship 9326308Authorship 936147614734467Simon R, Panussis S, Maurer R, Spichtin H, Glatz K, Tapia C, Mirlacher M, Rufle A, Torhorst J, Sauter GClinical cancer research : an official journal of the American Association for Cancer ResearchKIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):178-83.Clin Cancer Res2004-01-01T00:00:002004KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations.21315418Tapia C, Zlobec I, Schneider S, Kilic E, G?th U, Bubendorf L, Kim SHuman pathologyDeletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer. Hum Pathol. 2011 Jul; 42(7):983-90.Hum Pathol2011-02-11T00:00:002011Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer.22471961Droeser R, Zlobec I, Kilic E, G?th U, Heberer M, Spagnoli G, Oertli D, Tapia CBMC cancerDifferential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer. 2012 Apr 03; 12:134.BMC Cancer2012-04-03T00:00:002012Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers.23056468Byron SA, Min E, Thal TS, Hostetter G, Watanabe AT, Azorsa DO, Little TH, Tapia C, Kim SPloS oneNegative regulation of NF-?B by the ING4 tumor suppressor in breast cancer. PLoS One. 2012; 7(10):e46823.PLoS One2012-10-04T00:00:002012Negative regulation of NF-?B by the ING4 tumor suppressor in breast cancer.26552477Grogg A, Trippel M, Pfaltz K, L?drach C, Droeser RA, Cihoric N, Salhia B, Zweifel M, Tapia CBMC cancerAndrogen receptor status is highly conserved during tumor progression of breast cancer. BMC Cancer. 2015 Nov 09; 15:872.BMC Cancer2015-11-09T00:00:002015Androgen receptor status is highly conserved during tumor progression of breast cancer.26965699Swisher SK, Wu Y, Castaneda CA, Lyons GR, Yang F, Tapia C, Wang X, Casavilca SA, Bassett R, Castillo M, Sahin A, Mittendorf EAAnnals of surgical oncologyInterobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Ann Surg Oncol. 2016 07; 23(7):2242-8.Ann Surg Oncol2016-03-10T00:00:002016Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.29093017Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam FClinical cancer research : an official journal of the American Association for Cancer ResearchA Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6468-6477.Clin Cancer Res2017-11-01T00:00:002017A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.30035249Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen KJCO precision oncologySurvival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018.JCO Precis Oncol2018-04-25T00:00:002018Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer.30345349Keene KS, King T, Hwang ES, Peng B, McGuire KP, Tapia C, Zhang H, Bae S, Nakhlis F, Klauber-Demore N, Meszoely I, Sabel MS, Willey SC, Eterovic AK, Hudis C, Wolff AC, De Los Santos J, Thompson A, Mills GB, Meric-Bernstam FNPJ breast cancerMolecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer. 2018; 4:34.NPJ Breast Cancer2018-10-12T00:00:002018Molecular determinants of post-mastectomy breast cancer recurrence.Department of PediatricsBaylor College of MedicineAuthorship 9432631430923315Adhikary S, Chakravarti D, Terranova C, Sengupta I, Maitituoheti M, Dasgupta A, Srivastava DK, Ma J, Raman AT, Tarco E, Sahin AA, Bassett R, Yang F, Tapia C, Roy S, Rai K, Das CNature communicationsAtypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor. Nat Commun. 2019 03 28; 10(1):1398.Nat Commun2019-03-28T00:00:002019Atypical plant homeodomain of UBR7 functions as an H2BK120Ub ligase and breast tumor suppressor.D00007432244812500.493987Antineoplastic Agents, ImmunologicalD061067Chemicals & Drugs75932360.439596Antibodies, Monoclonal, HumanizedAuthorship 9541991531433055Tew BY, Legendre C, Schroeder MA, Triche T, Gooden GC, Huang Y, Butry L, Ma DJ, Johnson K, Martinez RA, Pierobon M, Petricoin EF, O'shaughnessy J, Osborne C, Tapia C, Buckley DN, Glen J, Bernstein M, Sarkaria JN, Toms SA, Salhia BNeuro-oncologyPatient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones. Neuro Oncol. 2020 01 11; 22(1):70-83.Neuro Oncol2020-01-11T00:00:002020Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones.Authorship 954994531489111Owusu-Brackett N, Evans KW, Akcakanat A, Yuca E, Tapia C, Rizvi YQ, Dumbrava EI, Janku F, Meric-Bernstam FOncotargetTAK228 enhances antitumor activity of eribulin in triple negative breast cancer. Oncotarget. 2019 Aug 20; 10(49):5011-5019.Oncotarget2019-08-20T00:00:002019TAK228 enhances antitumor activity of eribulin in triple negative breast cancer.Authorship 9556973Authorship 955723531532833Creasy CA, Forget MA, Singh G, Tapia C, Xu M, Stephen B, Sabir S, Meric-Bernstam F, Haymaker C, Bernatchez C, Naing AEuropean journal of immunologyExposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors. Eur J Immunol. 2019 12; 49(12):2245-2251.Eur J Immunol2019-09-30T00:00:002019Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors.31533818Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, Fu S, Karp DD, Meric-Bernstam F, Naing AJournal for immunotherapy of cancerPhase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253.J Immunother Cancer2019-09-18T00:00:002019Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma.Pediatrics-Immu, Allergy & RetrovirJOUDHAJJARJOUD HAJJAR0.000000000000000.000000000000006080HAJJAR, JOUD0000-0003-4633-1043Associate ProfessorAuthorship 9793781632188704Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MAJournal for immunotherapy of cancerPhase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).J Immunother Cancer2020-03-01T00:00:002020Phase 2 study of pembrolizumab in patients with advanced rare cancers.Authorship 987625132303619Tapia C, Aung PP, Roy-Chowdhuri S, Xu M, Ouyang F, Alshawa A, Hajjar J, Singh G, Yang V, Castillo L, Le H, Murthy R, Stephen B, Hess KR, Wistuba I, Naing AJournal for immunotherapy of cancerDecrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2020 04; 8(1).J Immunother Cancer2020-04-01T00:00:002020Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors.Authorship 99637412Authorship 996375224661323Cihoric N, Tapia C, Kr?ger K, Aebersold DM, Klaeser B, L?ssl KRadiation oncology (London, England)IMRT with ?8FDG-PET\CT based simultaneous integrated boost for treatment of nodal positive cervical cancer. Radiat Oncol. 2014 Mar 25; 9:83.Radiat Oncol2014-03-25T00:00:002014IMRT with ?8FDG-PET\CT based simultaneous integrated boost for treatment of nodal positive cervical cancer.16882699Al-Kuraya K, Novotny H, Bavi P, Siraj AK, Uddin S, Ezzat A, Sanea NA, Al-Dayel F, Al-Mana H, Sheikh SS, Mirlacher M, Tapia C, Simon R, Sauter G, Terracciano L, Tornillo LJournal of clinical pathologyHER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J Clin Pathol. 2007 Jul; 60(7):768-72.J Clin Pathol2006-08-01T00:00:002006HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer.@HajjarJoudTwitter Tweets Harvard TweetsAuthorship 101245612Authorship 10127541217511881Tapia C, Savic S, Wagner U, Sch?negg R, Novotny H, Grilli B, Herzog M, Barascud AD, Zlobec I, Cathomas G, Terracciano L, Feichter G, Bubendorf LBreast cancer research : BCRHER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res. 2007; 9(3):R31.Breast Cancer Res2007-01-01T00:00:002007HER2 gene status in primary breast cancers and matched distant metastases.33663585Pairawan S, Zhao M, Yuca E, Annis A, Evans K, Sutton D, Carvajal L, Ren JG, Santiago S, Guerlavais V, Akcakanat A, Tapia C, Yang F, Bose PSC, Zheng X, Dumbrava EI, Aivado M, Meric-Bernstam FBreast cancer research : BCRFirst in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models. Breast Cancer Res. 2021 03 04; 23(1):29.Breast Cancer Res2021-03-04T00:00:002021First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.Authorship 10196095Authorship 10196266Authorship 10196351Authorship 1019636125885288Varga Z, Cassoly E, Li Q, Oehlschlegel C, Tapia C, Lehr HA, Klingbiel D, Th?rlimann B, Ruhstaller TPloS oneStandardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study. PLoS One. 2015; 10(4):e0123435.PLoS One2015-04-17T00:00:002015Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study.15803183Al-Kuraya K, Schraml P, Sheikh S, Amr S, Torhorst J, Tapia C, Novotny H, Spichtin H, Maurer R, Mirlacher M, Simon R, Sauter GModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncPredominance of high-grade pathway in breast cancer development of Middle East women. Mod Pathol. 2005 Jul; 18(7):891-7.Mod Pathol2005-07-01T00:00:002005Predominance of high-grade pathway in breast cancer development of Middle East women.17361205Tapia C, Glatz K, Novotny H, Lugli A, Horcic M, Seemayer CA, Tornillo L, Terracciano L, Spichtin H, Mirlacher M, Simon R, Sauter GModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClose association between HER-2 amplification and overexpression in human tumors of non-breast origin. Mod Pathol. 2007 Feb; 20(2):192-8.Mod Pathol2007-02-01T00:00:002007Close association between HER-2 amplification and overexpression in human tumors of non-breast origin.15547690Tapia C, Schraml P, Simon R, Al-Kuraya KS, Maurer R, Mirlacher M, Novotny H, Spichtin H, Mihatsch MJ, Sauter GInternational journal of oncologyHER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies. Int J Oncol. 2004 Dec; 25(6):1551-7.Int J Oncol2004-12-01T00:00:002004HER2 analysis in breast cancer: reduced immunoreactivity in FISH non-informative cancer biopsies.Authorship 1020741734108622Shariati M, Evans KW, Zheng X, Bristow CA, Ng PK, Rizvi YQ, Tapia C, Yang F, Carugo A, Heffernan TP, Peoples MD, Tripathy D, Meric-Bernstam FOncogeneCombined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations. Oncogene. 2021 07; 40(26):4425-4439.Oncogene2021-06-09T00:00:002021Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.34518211Evans KW, Yuca E, Scott SS, Zhao M, Paez Arango N, Cruz Pico CX, Saridogan T, Shariati M, Class CA, Bristow CA, Vellano CP, Zheng X, Gonzalez-Angulo AM, Su X, Tapia C, Chen K, Akcakanat A, Lim B, Tripathy D, Yap TA, Francesco MED, Draetta GF, Jones P, Heffernan TP, Marszalek JR, Meric-Bernstam FCancer researchOxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer. Cancer Res. 2021 11 01; 81(21):5572-5581.Cancer Res2021-09-13T00:00:002021Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.Authorship 10295564Authorship 10296661515574759Al-Kuraya K, Schraml P, Torhorst J, Tapia C, Zaharieva B, Novotny H, Spichtin H, Maurer R, Mirlacher M, K?chli O, Zuber M, Dieterich H, Mross F, Wilber K, Simon R, Sauter GCancer researchPrognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 2004 Dec 01; 64(23):8534-40.Cancer Res2004-12-01T00:00:002004Prognostic relevance of gene amplifications and coamplifications in breast cancer.Authorship 1035342231562818Imboden S, Tapia C, Scheiwiller N, Kocbek V, Altermatt HJ, Janzen J, Mueller MD, McKinnon BActa obstetricia et gynecologica ScandinavicaEarly-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence. Acta Obstet Gynecol Scand. 2020 02; 99(2):196-203.Acta Obstet Gynecol Scand2019-11-07T00:00:002019Early-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence.Authorship 1036104722011582Ariazi EA, Cunliffe HE, Lewis-Wambi JS, Slifker MJ, Willis AL, Ramos P, Tapia C, Kim HR, Yerrum S, Sharma CG, Nicolas E, Balagurunathan Y, Ross EA, Jordan VCProceedings of the National Academy of Sciences of the United States of AmericaEstrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A. 2011 Nov 22; 108(47):18879-86.Proc Natl Acad Sci U S A2011-10-19T00:00:002011Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time.Authorship 1040487435075200Pairawan S, Akcakanat A, Kopetz S, Tapia C, Zheng X, Chen H, Ha MJ, Rizvi Y, Holla V, Wang J, Evans KW, Zhao M, Busaidy N, Fang B, Roth JA, Dumbrava EI, Meric-Bernstam FScientific reportsCombined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep. 2022 01 24; 12(1):1248.Sci Rep2022-01-24T00:00:002022Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations.Authorship 1047607235663531Xu M, Tapia C, Hajjar J, Sabir S, Colen R, Nagarajan P, Aung PP, Gong J, Rodon J, Fu S, Stephen B, Roy-Chowdhuri S, Le H, Yang V, Zarifa A, Abdelsalam ME, Jhingran A, Javle M, Pant S, Carter B, Milton DR, Sun R, Karp DD, Koay EJ, Yang Y, Wistuba II, Hwu P, Meric-Bernstam F, Naing AJournal of immunotherapy and precision oncologyImplementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. J Immunother Precis Oncol. 2021 May; 4(2):45-52.J Immunother Precis Oncol2021-05-14T00:00:002021Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens. Navigating the Ultra-rare Landscape: The Relevance of P Navigating the Ultra-rare Landscape: The Relevance of P Long-Term Effects of Primary Immunodeficiency Navigating the Ultra-rare Landscape: The Relevance of P Long-Term Effects of Primary Immunodeficiency For Women with PI: Facing the Phases of Life Navigating the Ultra-rare Landscape: The Relevance of P Long-Term Effects of Primary Immunodeficiency For Women with PI: Facing the Phases of Life Fatigue, Pain & PI: What Do We Know?true1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessor